Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoking Cessation 1 Motor Activity 1 Lung Neoplasms 1 Inflammation 1

Interventions

Cisplatin 1519 Carboplatin 1420 Cyclophosphamide 1360 Gemcitabine 1235 Bevacizumab 1226 Paclitaxel 1211 Radiotherapy 1176 Docetaxel 1080 pembrolizumab 1028 Oxaliplatin 936 Capecitabine 901 Fluorouracil 833 Rituximab 729 Doxorubicin 683 Nivolumab 679 Dexamethasone 666 Etoposide 660 Irinotecan 622 Leucovorin 575 Pemetrexed 510 Drug Therapy 493 Cetuximab 483 Trastuzumab 469 Cytarabine 466 Magnetic Resonance Spectroscopy 458 Filgrastim 446 Prednisone 433 Lenalidomide 409 Specimen Handling 408 Temozolomide 400

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × cytisine × Clear all

NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡